Research comparison
CJC-1295 vs Sermorelin
Side-by-side comparison of research status, mechanisms, pharmacokinetics, and administration routes.
CJC-1295 is a modified GHRH analog with a Drug Affinity Complex (DAC) that binds to serum albumin, dramatically extending its half-life compared to native GHRH. It produces sustained elevation of GH and IGF-1 levels over days rather than hours. Research focuses on body composition improvements, muscle growth, and fat loss through prolonged GH axis stimulation.
Research Status
Preclinical Research
Half-Life
6–8 days (due to DAC albumin binding)
Molecular Formula
C₁₅₂H₂₅₂N₄₂O₄₂S
Molecular Weight
3647.28 Da
CAS Number
863288-34-0
Research Categories
Growth Hormone Axis
Routes of Administration
Sermorelin is a synthetic analog of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It stimulates the pituitary to produce and secrete growth hormone in a pulsatile, physiologic manner. FDA-approved for GH deficiency in children, it is extensively researched in adults for body composition, sleep quality, and age-related GH decline.
Research Status
FDA Approved
Half-Life
10–20 minutes
Molecular Formula
C₁₄₉H₂₄₆N₄₄O₄₂S
Molecular Weight
3357.88 Da
CAS Number
86168-78-7
Research Categories
Growth Hormone Axis, Anti-Aging & Longevity
Routes of Administration
Full mechanism comparison
Mechanism of action, pharmacokinetics, and research findings comparison available on the Researcher plan.
Unlock full comparison →Related comparisons